News Snapshot:
The Russia Ministry of Health has approved BeiGene’s Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL). Brukinsa is approved in nine countries to treat mantle cell lymphoma. Credit: Gabriel Caponetti / commons.wikimedia.org. The Russia Ministry of Health has approved BeiGene’s Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL). Brukinsa is Bruton’s tyrosine kinase (BTK) molecule inhibitor and is currently being evaluated as a monotherapy as well as in combination with other therapeutics for the treatment of several B-cell malignancies. The regulatory approval is based on data obtained from two single-arm...
